Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.59 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30195130 | 1.00 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL12107793 | 0.89 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL30195173 | 0.89 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL11833495 | 0.88 | EHMT2 (0.70) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL463670 | 0.87 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL23963850 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL3487114 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL10077568 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL31291173 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL19104359 | 0.86 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492263-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20230323434-A1 | GENERATING CAPTURE PROBES FOR SPATIAL ANALYSIS | 10X GENOMICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023180953-A1 | INHIBITORS OF HUMAN SLC7A3 FOR THE TREATMENT OF ENDOMETRIOSIS OR UTERINE FIBROIDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022106703-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2022-05-27 | — | — | WO | disclosed |
| CN-113039191-A | Nucleotide analogs | 奇异基因组学系统公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3448864-B1 | SILSESQUIOXANES AS TRANSPORT COMPOUNDS | UNIV DARMSTADT TECH (DE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3782654-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3569251-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | Endocyte, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20070269806-A1 | Polynucleotide Arrays | ILLUMINA CAMBRIDGE LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| WO-2007127473-A2 | POLY (ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-5413913-A | Autoagglutination prevention; medical diagnosis | AGEN BIOMEDICAL, LTD. (AU) | 1995-05-09 | — | — | US | disclosed |
| EP-0308242-B1 | Agglutination assay | AGEN LTD (AU) | 1995-01-04 | — | — | EP | disclosed |
| US-5086002-A | Detecting antigen, antibody | AGEN BIOMEDICAL, LTD. (AU) | 1992-02-04 | — | — | US | disclosed |
| EP-0308242-A2 | Agglutination assay | AGEN LIMITED (AU) | 1989-03-22 | — | — | EP | disclosed |
| US-4237290-A | ODORANTS, FLAVORINGS; REACTION OF A SULFONIUM SALT AND A MERCAPTAN | GIVAUDAN CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
| US-4188488-A | ALKYLIMIDAZOLYL SUBSTITUENTS | GIVAUDAN CORPORATION (US) | 1980-02-12 | — | — | US | disclosed |
| US-4170594-A | Oxazolyl-alkyl-disulphides as flavorants | GIVAUDAN CORPORATION (US) | 1979-10-09 | — | — | US | disclosed |
| US-4130562-A | Odorant or flavoring thiazolyl disulphides | GIVAUDAN CORPORATION (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492263-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | EHMT2 1031/4885EHMT1 2274/4885APOBEC3G 1092/4885 |
| US-20070269806-A1 | Polynucleotide Arrays | PCNA, NCL, POLN | EHMT2 2094/4885EHMT1 2492/4885APOBEC3G 271/4885 |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | EHMT2 1031/4885EHMT1 2274/4885APOBEC3G 1092/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | EHMT2 3727/4885EHMT1 3809/4885APOBEC3G 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.